Please try another search
For the fiscal year ended 31 December 2016, Fluoropharma Medical Inc revenues was not reported. Net loss applicable to common stockholders decreased 31% to $2.6M. Lower net loss reflects Gain on revaln of derivative warrant lia increase from $716K to $2.3M (income), General and administrative decrease of 31% to $1.7M (expense), Research and development decrease of 29% to $511K (expense).
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.52 | -0.32 | -0.66 | -1.7 |
Net Income | -0.13 | 0.38 | -0.73 | -1.57 |
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Total Assets | 0.33 | 0.39 | 0.77 | 0.46 |
Total Liabilities | 10.51 | 10.32 | 10.96 | 9.91 |
Total Equity | -10.18 | -9.93 | -10.19 | -9.45 |
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -0.88 | -0.76 | -0.23 | -0.39 |
Cash From Investing Activities | -0 | -0 | -0 | 0 |
Cash From Financing Activities | 0.62 | 0.5 | 0.35 | 0.14 |
Net Change in Cash | -0.27 | -0.26 | 0.12 | -0.25 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review